nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—CYP3A4—bone cancer	0.358	1	CbGaD
Lovastatin—UGT2B7—Epirubicin—bone cancer	0.133	0.271	CbGbCtD
Lovastatin—ABCC2—Carboplatin—bone cancer	0.065	0.132	CbGbCtD
Lovastatin—ABCC2—Cisplatin—bone cancer	0.0556	0.113	CbGbCtD
Lovastatin—SLCO1A2—Methotrexate—bone cancer	0.0435	0.0886	CbGbCtD
Lovastatin—SLCO1B1—Methotrexate—bone cancer	0.0411	0.0836	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—bone cancer	0.0372	0.0758	CbGbCtD
Lovastatin—ABCC2—Methotrexate—bone cancer	0.0361	0.0735	CbGbCtD
Lovastatin—CYP2C9—Cisplatin—bone cancer	0.0187	0.038	CbGbCtD
Lovastatin—ABCB1—Cisplatin—bone cancer	0.0181	0.0369	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—bone cancer	0.0121	0.0247	CbGbCtD
Lovastatin—ABCB1—Methotrexate—bone cancer	0.0118	0.0239	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—bone cancer	0.0114	0.0233	CbGbCtD
Lovastatin—CYP3A4—Doxorubicin—bone cancer	0.00727	0.0148	CbGbCtD
Lovastatin—Memory loss—Cisplatin—bone cancer	0.00252	0.0471	CcSEcCtD
Lovastatin—Simvastatin—CYP3A4—bone cancer	0.00157	0.505	CrCbGaD
Lovastatin—Cognitive impairment—Methotrexate—bone cancer	0.00156	0.0291	CcSEcCtD
Lovastatin—Pravastatin—CYP3A4—bone cancer	0.00154	0.495	CrCbGaD
Lovastatin—Nodule—Methotrexate—bone cancer	0.00138	0.0258	CcSEcCtD
Lovastatin—Cognitive disorder—Methotrexate—bone cancer	0.00094	0.0176	CcSEcCtD
Lovastatin—Infection—Carboplatin—bone cancer	0.000895	0.0167	CcSEcCtD
Lovastatin—Loss of libido—Methotrexate—bone cancer	0.00088	0.0164	CcSEcCtD
Lovastatin—Tenderness—Cisplatin—bone cancer	0.000849	0.0159	CcSEcCtD
Lovastatin—Pain—Carboplatin—bone cancer	0.00077	0.0144	CcSEcCtD
Lovastatin—Body temperature increased—Carboplatin—bone cancer	0.000712	0.0133	CcSEcCtD
Lovastatin—Transaminases increased—Epirubicin—bone cancer	0.000625	0.0117	CcSEcCtD
Lovastatin—Haemolytic anaemia—Cisplatin—bone cancer	0.000595	0.0111	CcSEcCtD
Lovastatin—Transaminases increased—Doxorubicin—bone cancer	0.000578	0.0108	CcSEcCtD
Lovastatin—Amnesia—Cisplatin—bone cancer	0.000572	0.0107	CcSEcCtD
Lovastatin—Cramp muscle—Cisplatin—bone cancer	0.000484	0.00904	CcSEcCtD
Lovastatin—Pancreatitis—Cisplatin—bone cancer	0.000456	0.00851	CcSEcCtD
Lovastatin—Abdominal discomfort—Cisplatin—bone cancer	0.000445	0.00832	CcSEcCtD
Lovastatin—Jaundice cholestatic—Epirubicin—bone cancer	0.000433	0.00809	CcSEcCtD
Lovastatin—Vasculitis—Methotrexate—bone cancer	0.000416	0.00778	CcSEcCtD
Lovastatin—Neuropathy peripheral—Cisplatin—bone cancer	0.000406	0.00759	CcSEcCtD
Lovastatin—Jaundice cholestatic—Doxorubicin—bone cancer	0.0004	0.00748	CcSEcCtD
Lovastatin—Musculoskeletal pain—Epirubicin—bone cancer	0.000385	0.00719	CcSEcCtD
Lovastatin—Phosphatase alkaline increased—Epirubicin—bone cancer	0.00038	0.0071	CcSEcCtD
Lovastatin—Gynaecomastia—Methotrexate—bone cancer	0.000364	0.00679	CcSEcCtD
Lovastatin—Musculoskeletal pain—Doxorubicin—bone cancer	0.000356	0.00665	CcSEcCtD
Lovastatin—Phosphatase alkaline increased—Doxorubicin—bone cancer	0.000352	0.00657	CcSEcCtD
Lovastatin—Flushing—Cisplatin—bone cancer	0.000345	0.00645	CcSEcCtD
Lovastatin—Photosensitivity—Methotrexate—bone cancer	0.000336	0.00628	CcSEcCtD
Lovastatin—Alopecia—Cisplatin—bone cancer	0.000329	0.00614	CcSEcCtD
Lovastatin—Hepatic failure—Methotrexate—bone cancer	0.000328	0.00613	CcSEcCtD
Lovastatin—Flatulence—Cisplatin—bone cancer	0.000319	0.00596	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Epirubicin—bone cancer	0.000317	0.00593	CcSEcCtD
Lovastatin—Hepatic function abnormal—Epirubicin—bone cancer	0.000316	0.0059	CcSEcCtD
Lovastatin—Photosensitivity—Epirubicin—bone cancer	0.000314	0.00587	CcSEcCtD
Lovastatin—Muscle spasms—Cisplatin—bone cancer	0.000311	0.00581	CcSEcCtD
Lovastatin—Vascular purpura—Epirubicin—bone cancer	0.000309	0.00576	CcSEcCtD
Lovastatin—Hepatic failure—Epirubicin—bone cancer	0.000307	0.00574	CcSEcCtD
Lovastatin—Vision blurred—Cisplatin—bone cancer	0.000305	0.0057	CcSEcCtD
Lovastatin—Tremor—Cisplatin—bone cancer	0.000303	0.00567	CcSEcCtD
Lovastatin—Ill-defined disorder—Cisplatin—bone cancer	0.0003	0.00561	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Doxorubicin—bone cancer	0.000294	0.00549	CcSEcCtD
Lovastatin—Hepatic function abnormal—Doxorubicin—bone cancer	0.000292	0.00546	CcSEcCtD
Lovastatin—Malaise—Cisplatin—bone cancer	0.000292	0.00545	CcSEcCtD
Lovastatin—Photosensitivity—Doxorubicin—bone cancer	0.000291	0.00543	CcSEcCtD
Lovastatin—Leukopenia—Cisplatin—bone cancer	0.00029	0.00541	CcSEcCtD
Lovastatin—Purpura—Epirubicin—bone cancer	0.000286	0.00535	CcSEcCtD
Lovastatin—Vascular purpura—Doxorubicin—bone cancer	0.000286	0.00533	CcSEcCtD
Lovastatin—Hepatic failure—Doxorubicin—bone cancer	0.000284	0.00531	CcSEcCtD
Lovastatin—Pain in extremity—Epirubicin—bone cancer	0.000276	0.00516	CcSEcCtD
Lovastatin—Myalgia—Cisplatin—bone cancer	0.000276	0.00515	CcSEcCtD
Lovastatin—Anxiety—Cisplatin—bone cancer	0.000275	0.00513	CcSEcCtD
Lovastatin—Discomfort—Cisplatin—bone cancer	0.000272	0.00509	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000266	0.00496	CcSEcCtD
Lovastatin—Purpura—Doxorubicin—bone cancer	0.000265	0.00495	CcSEcCtD
Lovastatin—Anaphylactic shock—Cisplatin—bone cancer	0.000264	0.00494	CcSEcCtD
Lovastatin—Infection—Cisplatin—bone cancer	0.000262	0.0049	CcSEcCtD
Lovastatin—Thrombocytopenia—Cisplatin—bone cancer	0.000259	0.00483	CcSEcCtD
Lovastatin—Pain in extremity—Doxorubicin—bone cancer	0.000255	0.00477	CcSEcCtD
Lovastatin—Eosinophilia—Methotrexate—bone cancer	0.000252	0.00472	CcSEcCtD
Lovastatin—Anorexia—Cisplatin—bone cancer	0.000252	0.0047	CcSEcCtD
Lovastatin—Pancreatitis—Methotrexate—bone cancer	0.00025	0.00467	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000249	0.00464	CcSEcCtD
Lovastatin—Abdominal discomfort—Methotrexate—bone cancer	0.000244	0.00457	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000241	0.0045	CcSEcCtD
Lovastatin—Influenza—Epirubicin—bone cancer	0.000239	0.00446	CcSEcCtD
Lovastatin—Paraesthesia—Cisplatin—bone cancer	0.000237	0.00443	CcSEcCtD
Lovastatin—Eosinophilia—Epirubicin—bone cancer	0.000236	0.00441	CcSEcCtD
Lovastatin—Dyspnoea—Cisplatin—bone cancer	0.000236	0.0044	CcSEcCtD
Lovastatin—Erectile dysfunction—Methotrexate—bone cancer	0.000235	0.00439	CcSEcCtD
Lovastatin—Pancreatitis—Epirubicin—bone cancer	0.000234	0.00437	CcSEcCtD
Lovastatin—Photosensitivity reaction—Methotrexate—bone cancer	0.000233	0.00435	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00023	0.0043	CcSEcCtD
Lovastatin—Decreased appetite—Cisplatin—bone cancer	0.00023	0.00429	CcSEcCtD
Lovastatin—Pain—Cisplatin—bone cancer	0.000226	0.00422	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000225	0.00421	CcSEcCtD
Lovastatin—Influenza—Doxorubicin—bone cancer	0.000221	0.00412	CcSEcCtD
Lovastatin—Eosinophilia—Doxorubicin—bone cancer	0.000219	0.00408	CcSEcCtD
Lovastatin—Photosensitivity reaction—Epirubicin—bone cancer	0.000218	0.00407	CcSEcCtD
Lovastatin—Feeling abnormal—Cisplatin—bone cancer	0.000218	0.00407	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—bone cancer	0.000216	0.00404	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000211	0.00394	CcSEcCtD
Lovastatin—Body temperature increased—Cisplatin—bone cancer	0.000209	0.0039	CcSEcCtD
Lovastatin—Neuropathy peripheral—Epirubicin—bone cancer	0.000209	0.0039	CcSEcCtD
Lovastatin—Urinary tract infection—Epirubicin—bone cancer	0.000207	0.00386	CcSEcCtD
Lovastatin—Hepatitis—Methotrexate—bone cancer	0.000204	0.00381	CcSEcCtD
Lovastatin—Photosensitivity reaction—Doxorubicin—bone cancer	0.000202	0.00376	CcSEcCtD
Lovastatin—Sinusitis—Epirubicin—bone cancer	0.0002	0.00373	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000195	0.00365	CcSEcCtD
Lovastatin—Hypersensitivity—Cisplatin—bone cancer	0.000195	0.00364	CcSEcCtD
Lovastatin—Erythema multiforme—Methotrexate—bone cancer	0.000193	0.0036	CcSEcCtD
Lovastatin—Neuropathy peripheral—Doxorubicin—bone cancer	0.000193	0.0036	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—bone cancer	0.000191	0.00357	CcSEcCtD
Lovastatin—Hepatitis—Epirubicin—bone cancer	0.000191	0.00357	CcSEcCtD
Lovastatin—Asthenia—Cisplatin—bone cancer	0.00019	0.00354	CcSEcCtD
Lovastatin—Sinusitis—Doxorubicin—bone cancer	0.000185	0.00345	CcSEcCtD
Lovastatin—Chills—Methotrexate—bone cancer	0.000183	0.00342	CcSEcCtD
Lovastatin—Diarrhoea—Cisplatin—bone cancer	0.000181	0.00338	CcSEcCtD
Lovastatin—Erythema multiforme—Epirubicin—bone cancer	0.000181	0.00337	CcSEcCtD
Lovastatin—Alopecia—Methotrexate—bone cancer	0.00018	0.00337	CcSEcCtD
Lovastatin—Flushing—Epirubicin—bone cancer	0.000177	0.00331	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—bone cancer	0.000177	0.0033	CcSEcCtD
Lovastatin—Dysgeusia—Methotrexate—bone cancer	0.000174	0.00325	CcSEcCtD
Lovastatin—Back pain—Methotrexate—bone cancer	0.000172	0.00321	CcSEcCtD
Lovastatin—Chills—Epirubicin—bone cancer	0.000171	0.0032	CcSEcCtD
Lovastatin—Alopecia—Epirubicin—bone cancer	0.000169	0.00315	CcSEcCtD
Lovastatin—Vomiting—Cisplatin—bone cancer	0.000168	0.00314	CcSEcCtD
Lovastatin—Vision blurred—Methotrexate—bone cancer	0.000167	0.00313	CcSEcCtD
Lovastatin—Erythema multiforme—Doxorubicin—bone cancer	0.000167	0.00312	CcSEcCtD
Lovastatin—Rash—Cisplatin—bone cancer	0.000167	0.00311	CcSEcCtD
Lovastatin—Dermatitis—Cisplatin—bone cancer	0.000166	0.00311	CcSEcCtD
Lovastatin—Ill-defined disorder—Methotrexate—bone cancer	0.000165	0.00308	CcSEcCtD
Lovastatin—Flushing—Doxorubicin—bone cancer	0.000164	0.00306	CcSEcCtD
Lovastatin—Flatulence—Epirubicin—bone cancer	0.000164	0.00306	CcSEcCtD
Lovastatin—Dysgeusia—Epirubicin—bone cancer	0.000163	0.00304	CcSEcCtD
Lovastatin—Back pain—Epirubicin—bone cancer	0.000161	0.003	CcSEcCtD
Lovastatin—Malaise—Methotrexate—bone cancer	0.00016	0.00299	CcSEcCtD
Lovastatin—Muscle spasms—Epirubicin—bone cancer	0.00016	0.00299	CcSEcCtD
Lovastatin—Vertigo—Methotrexate—bone cancer	0.00016	0.00298	CcSEcCtD
Lovastatin—Leukopenia—Methotrexate—bone cancer	0.000159	0.00297	CcSEcCtD
Lovastatin—Chills—Doxorubicin—bone cancer	0.000159	0.00296	CcSEcCtD
Lovastatin—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000158	0.00168	CbGpPWpGaD
Lovastatin—HDAC2—Cell Cycle—MDM2—bone cancer	0.000158	0.00167	CbGpPWpGaD
Lovastatin—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000158	0.00167	CbGpPWpGaD
Lovastatin—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000157	0.00167	CbGpPWpGaD
Lovastatin—Nausea—Cisplatin—bone cancer	0.000157	0.00293	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—KIT—bone cancer	0.000157	0.00166	CbGpPWpGaD
Lovastatin—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000157	0.00166	CbGpPWpGaD
Lovastatin—Vision blurred—Epirubicin—bone cancer	0.000157	0.00293	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—bone cancer	0.000156	0.00292	CcSEcCtD
Lovastatin—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.000156	0.00165	CbGpPWpGaD
Lovastatin—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.000156	0.00165	CbGpPWpGaD
Lovastatin—HMGCR—AMPK Signaling—TP53—bone cancer	0.000155	0.00164	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—ATF1—bone cancer	0.000155	0.00164	CbGpPWpGaD
Lovastatin—Ill-defined disorder—Epirubicin—bone cancer	0.000154	0.00288	CcSEcCtD
Lovastatin—ABCC2—NRF2 pathway—GSTP1—bone cancer	0.000152	0.00161	CbGpPWpGaD
Lovastatin—ABCC2—NRF2 pathway—TGFBR2—bone cancer	0.000152	0.00161	CbGpPWpGaD
Lovastatin—Flatulence—Doxorubicin—bone cancer	0.000152	0.00283	CcSEcCtD
Lovastatin—Myalgia—Methotrexate—bone cancer	0.000151	0.00283	CcSEcCtD
Lovastatin—Arthralgia—Methotrexate—bone cancer	0.000151	0.00283	CcSEcCtD
Lovastatin—Chest pain—Methotrexate—bone cancer	0.000151	0.00283	CcSEcCtD
Lovastatin—Dysgeusia—Doxorubicin—bone cancer	0.000151	0.00281	CcSEcCtD
Lovastatin—Malaise—Epirubicin—bone cancer	0.00015	0.0028	CcSEcCtD
Lovastatin—HDAC2—Regulation of Telomerase—EGFR—bone cancer	0.00015	0.00158	CbGpPWpGaD
Lovastatin—Discomfort—Methotrexate—bone cancer	0.000149	0.00279	CcSEcCtD
Lovastatin—Vertigo—Epirubicin—bone cancer	0.000149	0.00279	CcSEcCtD
Lovastatin—Leukopenia—Epirubicin—bone cancer	0.000149	0.00278	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—bone cancer	0.000149	0.00278	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—bone cancer	0.000148	0.00276	CcSEcCtD
Lovastatin—Confusional state—Methotrexate—bone cancer	0.000146	0.00273	CcSEcCtD
Lovastatin—Anaphylactic shock—Methotrexate—bone cancer	0.000145	0.00271	CcSEcCtD
Lovastatin—Vision blurred—Doxorubicin—bone cancer	0.000145	0.00271	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000145	0.00153	CbGpPWpGaD
Lovastatin—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000144	0.00152	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—RB1—bone cancer	0.000144	0.00152	CbGpPWpGaD
Lovastatin—Infection—Methotrexate—bone cancer	0.000144	0.00269	CcSEcCtD
Lovastatin—Ill-defined disorder—Doxorubicin—bone cancer	0.000143	0.00267	CcSEcCtD
Lovastatin—Thrombocytopenia—Methotrexate—bone cancer	0.000142	0.00265	CcSEcCtD
Lovastatin—Myalgia—Epirubicin—bone cancer	0.000142	0.00264	CcSEcCtD
Lovastatin—Chest pain—Epirubicin—bone cancer	0.000142	0.00264	CcSEcCtD
Lovastatin—Arthralgia—Epirubicin—bone cancer	0.000142	0.00264	CcSEcCtD
Lovastatin—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000141	0.0015	CbGpPWpGaD
Lovastatin—Anxiety—Epirubicin—bone cancer	0.000141	0.00263	CcSEcCtD
Lovastatin—HMGCR—Metabolism—NT5C3A—bone cancer	0.000141	0.00149	CbGpPWpGaD
Lovastatin—Discomfort—Epirubicin—bone cancer	0.00014	0.00261	CcSEcCtD
Lovastatin—Malaise—Doxorubicin—bone cancer	0.000139	0.00259	CcSEcCtD
Lovastatin—UGT1A3—Metabolism—NDUFA12—bone cancer	0.000139	0.00147	CbGpPWpGaD
Lovastatin—Dry mouth—Epirubicin—bone cancer	0.000138	0.00259	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—bone cancer	0.000138	0.00258	CcSEcCtD
Lovastatin—Anorexia—Methotrexate—bone cancer	0.000138	0.00258	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—MMP2—bone cancer	0.000138	0.00146	CbGpPWpGaD
Lovastatin—Leukopenia—Doxorubicin—bone cancer	0.000138	0.00257	CcSEcCtD
Lovastatin—Confusional state—Epirubicin—bone cancer	0.000137	0.00256	CcSEcCtD
Lovastatin—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000137	0.00145	CbGpPWpGaD
Lovastatin—Anaphylactic shock—Epirubicin—bone cancer	0.000136	0.00253	CcSEcCtD
Lovastatin—Infection—Epirubicin—bone cancer	0.000135	0.00252	CcSEcCtD
Lovastatin—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000135	0.00143	CbGpPWpGaD
Lovastatin—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000134	0.00142	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Epirubicin—bone cancer	0.000133	0.00248	CcSEcCtD
Lovastatin—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000132	0.0014	CbGpPWpGaD
Lovastatin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000132	0.00247	CcSEcCtD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000131	0.00139	CbGpPWpGaD
Lovastatin—Insomnia—Methotrexate—bone cancer	0.000131	0.00245	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—bone cancer	0.000131	0.00245	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—bone cancer	0.000131	0.00245	CcSEcCtD
Lovastatin—Chest pain—Doxorubicin—bone cancer	0.000131	0.00245	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—bone cancer	0.000131	0.00244	CcSEcCtD
Lovastatin—HDAC2—Signaling by NOTCH—JUN—bone cancer	0.00013	0.00138	CbGpPWpGaD
Lovastatin—Paraesthesia—Methotrexate—bone cancer	0.00013	0.00243	CcSEcCtD
Lovastatin—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00013	0.00138	CbGpPWpGaD
Lovastatin—Discomfort—Doxorubicin—bone cancer	0.000129	0.00242	CcSEcCtD
Lovastatin—Anorexia—Epirubicin—bone cancer	0.000129	0.00242	CcSEcCtD
Lovastatin—Dyspnoea—Methotrexate—bone cancer	0.000129	0.00241	CcSEcCtD
Lovastatin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000129	0.00136	CbGpPWpGaD
Lovastatin—Dry mouth—Doxorubicin—bone cancer	0.000128	0.00239	CcSEcCtD
Lovastatin—Dyspepsia—Methotrexate—bone cancer	0.000128	0.00238	CcSEcCtD
Lovastatin—Confusional state—Doxorubicin—bone cancer	0.000127	0.00236	CcSEcCtD
Lovastatin—Decreased appetite—Methotrexate—bone cancer	0.000126	0.00235	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000126	0.00133	CbGpPWpGaD
Lovastatin—Anaphylactic shock—Doxorubicin—bone cancer	0.000126	0.00235	CcSEcCtD
Lovastatin—Fatigue—Methotrexate—bone cancer	0.000125	0.00234	CcSEcCtD
Lovastatin—Infection—Doxorubicin—bone cancer	0.000125	0.00233	CcSEcCtD
Lovastatin—HDAC2—Circadian rythm related genes—CDK4—bone cancer	0.000124	0.00131	CbGpPWpGaD
Lovastatin—Pain—Methotrexate—bone cancer	0.000124	0.00232	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000124	0.00231	CcSEcCtD
Lovastatin—ITGAL—Adaptive Immune System—MDM2—bone cancer	0.000124	0.00131	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—FUS—bone cancer	0.000123	0.0013	CbGpPWpGaD
Lovastatin—Thrombocytopenia—Doxorubicin—bone cancer	0.000123	0.0023	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—MDM2—bone cancer	0.000123	0.0013	CbGpPWpGaD
Lovastatin—Insomnia—Epirubicin—bone cancer	0.000123	0.00229	CcSEcCtD
Lovastatin—Paraesthesia—Epirubicin—bone cancer	0.000122	0.00228	CcSEcCtD
Lovastatin—Dyspnoea—Epirubicin—bone cancer	0.000121	0.00226	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—bone cancer	0.00012	0.00224	CcSEcCtD
Lovastatin—Feeling abnormal—Methotrexate—bone cancer	0.000119	0.00223	CcSEcCtD
Lovastatin—ABCC2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000119	0.00126	CbGpPWpGaD
Lovastatin—Dyspepsia—Epirubicin—bone cancer	0.000119	0.00223	CcSEcCtD
Lovastatin—Gastrointestinal pain—Methotrexate—bone cancer	0.000119	0.00221	CcSEcCtD
Lovastatin—Decreased appetite—Epirubicin—bone cancer	0.000118	0.0022	CcSEcCtD
Lovastatin—UGT2B7—Metabolism—NDUFA12—bone cancer	0.000118	0.00125	CbGpPWpGaD
Lovastatin—Fatigue—Epirubicin—bone cancer	0.000117	0.00219	CcSEcCtD
Lovastatin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000117	0.00124	CbGpPWpGaD
Lovastatin—HDAC2—Chromatin modifying enzymes—CDK4—bone cancer	0.000117	0.00123	CbGpPWpGaD
Lovastatin—Constipation—Epirubicin—bone cancer	0.000116	0.00217	CcSEcCtD
Lovastatin—Pain—Epirubicin—bone cancer	0.000116	0.00217	CcSEcCtD
Lovastatin—HDAC2—Hemostasis—SPARC—bone cancer	0.000115	0.00122	CbGpPWpGaD
Lovastatin—Urticaria—Methotrexate—bone cancer	0.000115	0.00215	CcSEcCtD
Lovastatin—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.000115	0.00122	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—NT5C3A—bone cancer	0.000115	0.00121	CbGpPWpGaD
Lovastatin—Abdominal pain—Methotrexate—bone cancer	0.000115	0.00214	CcSEcCtD
Lovastatin—Body temperature increased—Methotrexate—bone cancer	0.000115	0.00214	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000114	0.00214	CcSEcCtD
Lovastatin—Insomnia—Doxorubicin—bone cancer	0.000114	0.00212	CcSEcCtD
Lovastatin—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000113	0.0012	CbGpPWpGaD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000113	0.0012	CbGpPWpGaD
Lovastatin—Paraesthesia—Doxorubicin—bone cancer	0.000113	0.00211	CcSEcCtD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000112	0.00119	CbGpPWpGaD
Lovastatin—Dyspnoea—Doxorubicin—bone cancer	0.000112	0.00209	CcSEcCtD
Lovastatin—Feeling abnormal—Epirubicin—bone cancer	0.000112	0.00209	CcSEcCtD
Lovastatin—Gastrointestinal pain—Epirubicin—bone cancer	0.000111	0.00207	CcSEcCtD
Lovastatin—Dyspepsia—Doxorubicin—bone cancer	0.000111	0.00206	CcSEcCtD
Lovastatin—Decreased appetite—Doxorubicin—bone cancer	0.000109	0.00204	CcSEcCtD
Lovastatin—Fatigue—Doxorubicin—bone cancer	0.000108	0.00202	CcSEcCtD
Lovastatin—HDAC2—Glucocorticoid receptor regulatory network—TP53—bone cancer	0.000108	0.00114	CbGpPWpGaD
Lovastatin—Urticaria—Epirubicin—bone cancer	0.000108	0.00201	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—bone cancer	0.000107	0.00201	CcSEcCtD
Lovastatin—Pain—Doxorubicin—bone cancer	0.000107	0.00201	CcSEcCtD
Lovastatin—Body temperature increased—Epirubicin—bone cancer	0.000107	0.002	CcSEcCtD
Lovastatin—Abdominal pain—Epirubicin—bone cancer	0.000107	0.002	CcSEcCtD
Lovastatin—Hypersensitivity—Methotrexate—bone cancer	0.000107	0.002	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—JUN—bone cancer	0.000107	0.00113	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—GNA11—bone cancer	0.000105	0.00112	CbGpPWpGaD
Lovastatin—Asthenia—Methotrexate—bone cancer	0.000104	0.00194	CcSEcCtD
Lovastatin—Feeling abnormal—Doxorubicin—bone cancer	0.000103	0.00193	CcSEcCtD
Lovastatin—ABCC2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000103	0.00109	CbGpPWpGaD
Lovastatin—Gastrointestinal pain—Doxorubicin—bone cancer	0.000103	0.00192	CcSEcCtD
Lovastatin—Pruritus—Methotrexate—bone cancer	0.000103	0.00192	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism—NDUFA12—bone cancer	0.000103	0.00109	CbGpPWpGaD
Lovastatin—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.0001	0.00106	CbGpPWpGaD
Lovastatin—Hypersensitivity—Epirubicin—bone cancer	0.0001	0.00187	CcSEcCtD
Lovastatin—Urticaria—Doxorubicin—bone cancer	9.97e-05	0.00186	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—bone cancer	9.92e-05	0.00185	CcSEcCtD
Lovastatin—Abdominal pain—Doxorubicin—bone cancer	9.92e-05	0.00185	CcSEcCtD
Lovastatin—Diarrhoea—Methotrexate—bone cancer	9.92e-05	0.00185	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—EGFR—bone cancer	9.88e-05	0.00105	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—NT5C3A—bone cancer	9.76e-05	0.00103	CbGpPWpGaD
Lovastatin—Asthenia—Epirubicin—bone cancer	9.74e-05	0.00182	CcSEcCtD
Lovastatin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	9.71e-05	0.00103	CbGpPWpGaD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.68e-05	0.00102	CbGpPWpGaD
Lovastatin—Pruritus—Epirubicin—bone cancer	9.6e-05	0.00179	CcSEcCtD
Lovastatin—Dizziness—Methotrexate—bone cancer	9.59e-05	0.00179	CcSEcCtD
Lovastatin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	9.57e-05	0.00101	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—NDUFA12—bone cancer	9.57e-05	0.00101	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—IL3—bone cancer	9.56e-05	0.00101	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	9.55e-05	0.00101	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—KIT—bone cancer	9.52e-05	0.00101	CbGpPWpGaD
Lovastatin—Diarrhoea—Epirubicin—bone cancer	9.28e-05	0.00173	CcSEcCtD
Lovastatin—Hypersensitivity—Doxorubicin—bone cancer	9.25e-05	0.00173	CcSEcCtD
Lovastatin—Vomiting—Methotrexate—bone cancer	9.22e-05	0.00172	CcSEcCtD
Lovastatin—Rash—Methotrexate—bone cancer	9.14e-05	0.00171	CcSEcCtD
Lovastatin—Dermatitis—Methotrexate—bone cancer	9.13e-05	0.00171	CcSEcCtD
Lovastatin—Headache—Methotrexate—bone cancer	9.08e-05	0.0017	CcSEcCtD
Lovastatin—HDAC2—Cell Cycle—TP53—bone cancer	9.08e-05	0.000961	CbGpPWpGaD
Lovastatin—Asthenia—Doxorubicin—bone cancer	9.01e-05	0.00168	CcSEcCtD
Lovastatin—Dizziness—Epirubicin—bone cancer	8.97e-05	0.00168	CcSEcCtD
Lovastatin—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	8.93e-05	0.000946	CbGpPWpGaD
Lovastatin—Pruritus—Doxorubicin—bone cancer	8.88e-05	0.00166	CcSEcCtD
Lovastatin—HDAC2—Signaling by NGF—KIT—bone cancer	8.81e-05	0.000932	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—NDUFA12—bone cancer	8.77e-05	0.000928	CbGpPWpGaD
Lovastatin—Vomiting—Epirubicin—bone cancer	8.63e-05	0.00161	CcSEcCtD
Lovastatin—Nausea—Methotrexate—bone cancer	8.61e-05	0.00161	CcSEcCtD
Lovastatin—HDAC2—Signaling by NOTCH—TP53—bone cancer	8.61e-05	0.000911	CbGpPWpGaD
Lovastatin—Diarrhoea—Doxorubicin—bone cancer	8.59e-05	0.0016	CcSEcCtD
Lovastatin—Rash—Epirubicin—bone cancer	8.56e-05	0.0016	CcSEcCtD
Lovastatin—Dermatitis—Epirubicin—bone cancer	8.55e-05	0.0016	CcSEcCtD
Lovastatin—HDAC2—Gene Expression—NR1I2—bone cancer	8.53e-05	0.000903	CbGpPWpGaD
Lovastatin—Headache—Epirubicin—bone cancer	8.5e-05	0.00159	CcSEcCtD
Lovastatin—SLCO1A2—Metabolism—NT5C3A—bone cancer	8.5e-05	0.000899	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—EGFR—bone cancer	8.44e-05	0.000894	CbGpPWpGaD
Lovastatin—CYP2C8—Biological oxidations—CYP3A4—bone cancer	8.41e-05	0.00089	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—EGFR—bone cancer	8.39e-05	0.000888	CbGpPWpGaD
Lovastatin—CYP3A5—Biological oxidations—GSTP1—bone cancer	8.3e-05	0.000879	CbGpPWpGaD
Lovastatin—Dizziness—Doxorubicin—bone cancer	8.3e-05	0.00155	CcSEcCtD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—bone cancer	8.3e-05	0.000878	CbGpPWpGaD
Lovastatin—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	8.29e-05	0.000878	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—BRAF—bone cancer	8.28e-05	0.000876	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—TP53—bone cancer	8.2e-05	0.000868	CbGpPWpGaD
Lovastatin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	8.19e-05	0.000867	CbGpPWpGaD
Lovastatin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	8.15e-05	0.000862	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	8.12e-05	0.00086	CbGpPWpGaD
Lovastatin—Nausea—Epirubicin—bone cancer	8.06e-05	0.00151	CcSEcCtD
Lovastatin—CYP3A7—Metabolism—NDUFA12—bone cancer	8.05e-05	0.000852	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—JUN—bone cancer	7.99e-05	0.000846	CbGpPWpGaD
Lovastatin—Vomiting—Doxorubicin—bone cancer	7.98e-05	0.00149	CcSEcCtD
Lovastatin—UGT1A1—Metabolism—NT5C3A—bone cancer	7.93e-05	0.000839	CbGpPWpGaD
Lovastatin—Rash—Doxorubicin—bone cancer	7.92e-05	0.00148	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—bone cancer	7.91e-05	0.00148	CcSEcCtD
Lovastatin—Headache—Doxorubicin—bone cancer	7.87e-05	0.00147	CcSEcCtD
Lovastatin—CYP2C19—Biological oxidations—CYP3A4—bone cancer	7.51e-05	0.000794	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—MDM2—bone cancer	7.5e-05	0.000793	CbGpPWpGaD
Lovastatin—Nausea—Doxorubicin—bone cancer	7.46e-05	0.00139	CcSEcCtD
Lovastatin—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	7.4e-05	0.000783	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	7.4e-05	0.000783	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—NT5C3A—bone cancer	7.27e-05	0.000769	CbGpPWpGaD
Lovastatin—HDAC2—Factors involved in megakaryocyte development and platelet production—TP53—bone cancer	7.21e-05	0.000763	CbGpPWpGaD
Lovastatin—CYP2C8—Biological oxidations—GSTP1—bone cancer	7.19e-05	0.000761	CbGpPWpGaD
Lovastatin—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	7.09e-05	0.000751	CbGpPWpGaD
Lovastatin—HDAC2—Direct p53 effectors—TP53—bone cancer	7.05e-05	0.000746	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—MDM2—bone cancer	6.94e-05	0.000734	CbGpPWpGaD
Lovastatin—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.9e-05	0.000731	CbGpPWpGaD
Lovastatin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	6.84e-05	0.000724	CbGpPWpGaD
Lovastatin—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.81e-05	0.00072	CbGpPWpGaD
Lovastatin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	6.75e-05	0.000714	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.74e-05	0.000713	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—NT5C3A—bone cancer	6.67e-05	0.000706	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.64e-05	0.000703	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—JUN—bone cancer	6.52e-05	0.000689	CbGpPWpGaD
Lovastatin—CYP2C19—Biological oxidations—GSTP1—bone cancer	6.42e-05	0.000679	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—GRM4—bone cancer	6.4e-05	0.000677	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—RGS1—bone cancer	6.4e-05	0.000677	CbGpPWpGaD
Lovastatin—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	6.33e-05	0.00067	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—EIF2S1—bone cancer	6.3e-05	0.000667	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	6.3e-05	0.000666	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—PLAU—bone cancer	6.27e-05	0.000664	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—ENO2—bone cancer	6.17e-05	0.000653	CbGpPWpGaD
Lovastatin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.96e-05	0.00063	CbGpPWpGaD
Lovastatin—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.9e-05	0.000625	CbGpPWpGaD
Lovastatin—HDAC2—Disease—ENO2—bone cancer	5.89e-05	0.000623	CbGpPWpGaD
Lovastatin—CYP2C9—Biological oxidations—GSTP1—bone cancer	5.85e-05	0.000619	CbGpPWpGaD
Lovastatin—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.82e-05	0.000616	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NDUFA12—bone cancer	5.82e-05	0.000616	CbGpPWpGaD
Lovastatin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	5.77e-05	0.000611	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—DHFR—bone cancer	5.72e-05	0.000606	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.63e-05	0.000596	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.62e-05	0.000594	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—GRM1—bone cancer	5.55e-05	0.000587	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—EZH2—bone cancer	5.47e-05	0.000579	CbGpPWpGaD
Lovastatin—HDAC2—Disease—DHFR—bone cancer	5.46e-05	0.000578	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—GNA11—bone cancer	5.35e-05	0.000566	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—TP53—bone cancer	5.28e-05	0.000558	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—EGFR—bone cancer	5.12e-05	0.000542	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NDUFA12—bone cancer	5.04e-05	0.000533	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—ENO2—bone cancer	5.03e-05	0.000532	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—CYP3A4—bone cancer	4.85e-05	0.000513	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.85e-05	0.000513	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.82e-05	0.00051	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NT5C3A—bone cancer	4.82e-05	0.00051	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—EGFR—bone cancer	4.74e-05	0.000502	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—DHFR—bone cancer	4.66e-05	0.000494	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NDUFA12—bone cancer	4.5e-05	0.000476	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NDUFA12—bone cancer	4.39e-05	0.000465	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—GNA11—bone cancer	4.36e-05	0.000461	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—ENO2—bone cancer	4.28e-05	0.000452	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.18e-05	0.000442	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NT5C3A—bone cancer	4.18e-05	0.000442	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—GSTP1—bone cancer	4.15e-05	0.000439	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NDUFA12—bone cancer	4.14e-05	0.000438	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NDUFA12—bone cancer	4.1e-05	0.000434	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—DHFR—bone cancer	3.97e-05	0.00042	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TGFBR2—bone cancer	3.96e-05	0.000419	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—CYP3A4—bone cancer	3.95e-05	0.000418	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SMO—bone cancer	3.91e-05	0.000414	CbGpPWpGaD
Lovastatin—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.86e-05	0.000408	CbGpPWpGaD
Lovastatin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.81e-05	0.000403	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NT5C3A—bone cancer	3.73e-05	0.000394	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—ENO2—bone cancer	3.72e-05	0.000394	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—GNA11—bone cancer	3.71e-05	0.000392	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NT5C3A—bone cancer	3.64e-05	0.000385	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—GNA11—bone cancer	3.57e-05	0.000378	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—ENO2—bone cancer	3.47e-05	0.000368	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—DHFR—bone cancer	3.45e-05	0.000365	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NT5C3A—bone cancer	3.43e-05	0.000363	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NT5C3A—bone cancer	3.4e-05	0.00036	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—GSTP1—bone cancer	3.38e-05	0.000358	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—CYP3A4—bone cancer	3.36e-05	0.000356	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—ATF1—bone cancer	3.32e-05	0.000352	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IL3—bone cancer	3.24e-05	0.000343	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—GNA11—bone cancer	3.23e-05	0.000342	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—DHFR—bone cancer	3.22e-05	0.000341	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—ENO2—bone cancer	3.18e-05	0.000337	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.1e-05	0.000328	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—GNA11—bone cancer	3.01e-05	0.000319	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.98e-05	0.000316	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—DHFR—bone cancer	2.95e-05	0.000313	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.93e-05	0.00031	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—ENO2—bone cancer	2.92e-05	0.000309	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.91e-05	0.000308	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—GSTP1—bone cancer	2.87e-05	0.000304	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TGFBR2—bone cancer	2.77e-05	0.000293	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—GNA11—bone cancer	2.76e-05	0.000292	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—CYP3A4—bone cancer	2.73e-05	0.000289	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—DHFR—bone cancer	2.71e-05	0.000287	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NDUFA12—bone cancer	2.71e-05	0.000286	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KIT—bone cancer	2.7e-05	0.000286	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.69e-05	0.000285	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—IGF1R—bone cancer	2.61e-05	0.000276	CbGpPWpGaD
Lovastatin—HDAC2—Disease—BRAF—bone cancer	2.54e-05	0.000269	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—GNA11—bone cancer	2.53e-05	0.000268	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TP53—bone cancer	2.52e-05	0.000267	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—GSTP1—bone cancer	2.5e-05	0.000265	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—CYP3A4—bone cancer	2.5e-05	0.000265	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.49e-05	0.000263	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—GSTP1—bone cancer	2.34e-05	0.000247	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CYP3A4—bone cancer	2.3e-05	0.000243	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NT5C3A—bone cancer	2.24e-05	0.000237	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTGS2—bone cancer	2.15e-05	0.000227	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—GSTP1—bone cancer	2.14e-05	0.000226	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MDM2—bone cancer	2.13e-05	0.000225	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.12e-05	0.000224	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—ENO2—bone cancer	2.11e-05	0.000224	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTGS2—bone cancer	2.05e-05	0.000217	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—GSTP1—bone cancer	1.96e-05	0.000208	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—DHFR—bone cancer	1.96e-05	0.000207	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KIT—bone cancer	1.89e-05	0.0002	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GNA11—bone cancer	1.83e-05	0.000194	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—ENO2—bone cancer	1.83e-05	0.000194	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—BRAF—bone cancer	1.78e-05	0.000188	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.78e-05	0.000188	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTGS2—bone cancer	1.75e-05	0.000185	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—DHFR—bone cancer	1.7e-05	0.00018	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.66e-05	0.000176	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—ENO2—bone cancer	1.63e-05	0.000173	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—ENO2—bone cancer	1.59e-05	0.000169	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GNA11—bone cancer	1.59e-05	0.000168	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—DHFR—bone cancer	1.51e-05	0.00016	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—ENO2—bone cancer	1.5e-05	0.000159	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MDM2—bone cancer	1.49e-05	0.000158	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTGS2—bone cancer	1.49e-05	0.000158	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—ENO2—bone cancer	1.49e-05	0.000158	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—DHFR—bone cancer	1.48e-05	0.000156	CbGpPWpGaD
Lovastatin—HDAC2—Disease—EGFR—bone cancer	1.45e-05	0.000154	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CYP3A4—bone cancer	1.44e-05	0.000152	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.43e-05	0.000151	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—GSTP1—bone cancer	1.42e-05	0.00015	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GNA11—bone cancer	1.42e-05	0.00015	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—DHFR—bone cancer	1.39e-05	0.000147	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GNA11—bone cancer	1.38e-05	0.000146	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—DHFR—bone cancer	1.38e-05	0.000146	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GNA11—bone cancer	1.3e-05	0.000138	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTGS2—bone cancer	1.3e-05	0.000137	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—JUN—bone cancer	1.29e-05	0.000137	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GNA11—bone cancer	1.29e-05	0.000137	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CYP3A4—bone cancer	1.28e-05	0.000136	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.28e-05	0.000135	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MMP9—bone cancer	1.26e-05	0.000133	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CYP3A4—bone cancer	1.25e-05	0.000133	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—GSTP1—bone cancer	1.23e-05	0.00013	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTGS2—bone cancer	1.21e-05	0.000128	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CYP3A4—bone cancer	1.18e-05	0.000125	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CYP3A4—bone cancer	1.17e-05	0.000124	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.16e-05	0.000123	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTGS2—bone cancer	1.11e-05	0.000117	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—GSTP1—bone cancer	1.1e-05	0.000116	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—GSTP1—bone cancer	1.07e-05	0.000113	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—EGFR—bone cancer	1.02e-05	0.000108	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTGS2—bone cancer	1.02e-05	0.000108	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—GSTP1—bone cancer	1.01e-05	0.000107	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—GSTP1—bone cancer	1e-05	0.000106	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—ENO2—bone cancer	9.82e-06	0.000104	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—DHFR—bone cancer	9.11e-06	9.64e-05	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—bone cancer	8.55e-06	9.04e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GNA11—bone cancer	8.51e-06	9.01e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTGS2—bone cancer	7.36e-06	7.78e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—GSTP1—bone cancer	6.6e-06	6.99e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTGS2—bone cancer	6.37e-06	6.74e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTGS2—bone cancer	5.69e-06	6.02e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTGS2—bone cancer	5.55e-06	5.87e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTGS2—bone cancer	5.23e-06	5.54e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTGS2—bone cancer	5.19e-06	5.49e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTGS2—bone cancer	3.42e-06	3.62e-05	CbGpPWpGaD
